{"SPADE_UN_14455": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_14455", "Peptide Name": "LP-52", "Source": "Synthetic construct", "Family": "Retroviridae", "Gene": "Not found", "Sequence": "WEQKIEELLKKAEEQQKKNEEELKKLEX", "Sequence Length": 28, "UniProt Entry": ["http://www.uniprot.org/uniprot/P03377"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Antiviral"], "Target Organism": "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=13±1 pM);HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=4±0 pM);HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=5±1 pM);HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=17 pM);T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.01-1.86 nM);HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.06-0.34 nM);SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.01-0.04 nM).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "[Ref.30089693]TZM-bl cell:CC50=112.9 ± 2.21 μM;MT-4 cell:CC50=94.06± 4.97 μM;HEK293T cell:CC50=88.86± 6.68μM;PBMC:CC50=114.8± 12.68 μM.", "Binding Target": "membrane", "Linear/Cyclic": "Linear", "N-terminal Modification": "Acetylation", "C-terminal Modification": "Amidation", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C150H247N39O49", "Mass": 3510.19, "PI": 5, "Net Charge": -2, "Hydrophobicity": -1.864, "Half Life": "Mammalian:2.8 hourYeast:3 minE.coli:2 min", "Mechanism of action": "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)", "Literature": [{"Title": "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.", "Pubmed ID": "30089693", "Reference": "J Virol. 2018 Sep 26;92(20)e01088-18.", "Author": "Chong H, Zhu Y, Yu D, He Y.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30089693"}], "Frequent Amino Acids": "EKL", "Absent Amino Acids": "CDFGHMOPRSTUVY", "Basic Residues": 7, "Acidic Residues": 9, "Hydrophobic Residues": 7, "Polar Residues": 12, "Positive Residues": 7, "Negative Residues": 9, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_14327", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNEEELKK"}, {"SPADE_ID": "SPADE_UN_14328", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNEEELK"}, {"SPADE_ID": "SPADE_UN_14329", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNEEE"}]}}}